logo
Sign In
Last Update: December 12, 2025
Prescribing informationFind savingsPubMed™ newsPatient education
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
  • Nascobal (Cyanocobalamin)

    Check Drug InteractionsCheck known drug interactions.
    Check Drug Interactions
    Find savings
    Get patient education materials
    PrescriberAI is currently offline. Try again later.

    By using PrescriberAI, you agree to the AI Terms of Use.

    This AI tool offers medical information for informational purposes only and is not a substitute for professional medical judgment or advice. Physicians and healthcare professionals should exercise their expertise and discretion when interpreting and applying the provided information to specific clinical situations.

    Nascobal prescribing information

    NASCOBAL is indicated for:

    • Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement
    • Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia
    • Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal

      Limitations of Use

    • NASCOBAL should not be used for the vitamin B12 absorption test (Schilling test).
    • In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long-term use of NASCOBAL following adequate correction of vitamin B12 deficiency and underlying disease has not been established.
    • The effectiveness of NASCOBAL in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with NASCOBAL should be deferred until symptoms have subsided.

    Nasal spray:  500 mcg/0.1 mL (per actuation), packaged in a single-use device containing 0.125 mL of solution

    NASCOBAL is contraindicated in patients with hypersensitivity to cobalt and/or vitamin B12 or any of its excipients

    [see Warnings and Precautions (5.2)]
    .  Anaphylactic shock and death have been reported after parenteral vitamin B12 administration in sensitive patients.

    The following serious adverse reactions are described elsewhere in the labeling:

    • Severe Optic Atrophy in Patients with Leber’s Disease
      [see Warnings and Precautions (5.1)]
      .
    • Anaphylactic Reactions
      [see Warnings and Precautions (5.2)]
      .
    • Hypokalemia and Thrombocytosis Due to Intense Treatment of Megaloblastic Anemia
      [see Warnings and Precautions (5.4)]
      .

    Chloramphenicol may decrease the efficacy of NASCOBAL when used for treatment of anemia. If NASCOBAL is used for the treatment of anemia concomitantly with chloramphenicol, monitor for reduced efficacy and if needed, consider an alternative therapy

    Cyanocobalamin is a synthetic form of vitamin B12. The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide. The cobalt content is 4.35%. The molecular formula is C63H88CoN14O14P, which corresponds to a molecular weight of 1355.38 and the following structural formula:

    Referenced Image

    Figure 1. Nascobal Chemical Structure

    Cyanocobalamin occurs as dark red crystals or orthorhombic needles or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly to moderately soluble in water (1:80). Its pharmacologic activity is destroyed by heavy metals (iron) and strong oxidizing or reducing agents (vitamin C), but not by autoclaving for short periods of time (15-20 minutes) at 121°C. The vitamin B12 coenzymes are very unstable in light.

    NASCOBAL (cyanocobalamin) nasal spray is a solution of cyanocobalamin, USP (vitamin B12) for administration as a spray to the nasal mucosa. Each single-use device of NASCOBAL NASAL SPRAY contains 0.125 mL of a 500 mcg/0.1 mL solution of cyanocobalamin with, benzalkonium chloride in purified water, citric acid, glycerin and sodium citrate. The spray solution has a pH between 4.5 and 5.5. Each spray delivers an average of 500 mcg of cyanocobalamin per actuation.

     

    We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    View more
    Report Adverse Event

    Nascobal PubMed™ news

      Nascobal patient education

      Patient toolkit